3rd Quarter - Report

JAZZ PHARMACEUTICALS, INC. for JAZZ PHARMACEUTICALS, INC.

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$460,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report (this page) Oct 18, 2024 $460,000 Replaced
3rd Quarter - Amendment Oct 22, 2024 $470,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

S.2860 - SAFER Banking Act HR 5539/ S. 3131 - Orphan Cures Act HR 8467 - Farm, Food, and National Security Act of 2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for Fiscal Year 2025 Control status of Epidiolex Changes to Inflation Reduction Act Drug safety, prescription drug abuse, value of prescription drugs Issues related to the regulation of cannabis and CBD Research and development of cannabis-derived therapies

LobbyistCovered position, as disclosed
MARK BOLTON —
KARAS GROSS —
VIRGINIA MCMILLIN —

Contacted: Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 2860 (118th), H.R. 5539 (118th), H.R. 8467 (118th), S. 3131 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.